Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : AMERICAN BIOMED, Minimally Invasive Technology (ABMI) -- Ignore unavailable to you. Want to Upgrade?

To: SIer formerly known as Joe B. who wrote (164)	3/14/1998 6:04:00 PM
From: Jeffrey L. Henken	Respond to of 2887

Check out one of the exciting products being developed by American BioMed. The OmniCath: What is the OmniCath? americanbiomed.com The OmniCathr Atherectomy Catheter The OmniCathr is an "atherectomy catheter," designed to allow physicians to remove atherosclerotic plaque from obstructed blood vessels throughout the body, thereby enlarging vessels narrowed by plaque, increasing a patient's blood flow. This is accomplished by removing the plaque with a cutting device, leaving the vessel wall, depending on technique, clean and smooth, free of fissures, ruptures and flaps. The OmniCath is in Phase II clinical trials for peripheral use. This is use throughout the body but not in the coronary arteries. The OmniCath is also being tested for use in AV Fistula cases. americanbiomed.com americanbiomed.com americanbiomed.com What is an AV Fistula? ARTERIOVENOUS FISTULA Abnormal communication between an artery and a vein. Etiology may be congenital, in which smaller vessels are involved, or acquired as a result of acute, local trauma (eg, from a bullet or stab wound) or of erosion of an arterial aneurysm into an accompanying vein. It may cause symptoms and signs of arterial insufficiency (including ulceration due to embolization and ischemia) or of chronic venous insufficiency due to the high-pressure arterial flow within the involved veins (including peripheral edema, venous varicosities, and stasis pigmentation). If near the surface, a mass can be felt and the affected part is usually enlarged and warm, with distended and often pulsating superficial veins. A thrill can be palpated over the fistula, and a continuous machinery murmur with accentuation during systole can be heard with the stethoscope. The altered hemodynamics may cause heart failure if a significant portion of the cardiac output is diverted through the fistula. The treatment of choice is surgery, if feasible. Market analysts have estimated the worldwide market potential for the OmniCath to be over $156-million annually for this indication. To the best of the Company's knowledge, there is no competitor in this market segment. Go ABMI! Regards, Jeff

To: SIer formerly known as Joe B. who wrote (164)	3/14/1998 6:22:00 PM
From: Jeffrey L. Henken	Respond to of 2887

Joe almost every chart you look at shares that error with the one at Yahoo. Please take a look at the historical pricing on ABMI and you will see that it never traded that low. As I was doing my due diligence on ABMI I went back and read as many of the old posts as I could find. Although Investors were very unhappy with the falling stock price they never complained about it reaching anything lower than the 23 cents I have confirmed it to have bottomed out at 23 cents. tradepbs.com I think if you are truly researching ABMI as an investment that you will find a tremendous amount of due diligence provided for you right from the beginning of this thread. Please take the time to read the posts. I would like to use my time this weekend to provide more information for new investors rather than covering old ground. If you are concerned about the widespread mistake that appears on all those charts concerning ABMI's price I suggest you complain to the provider of the chart. Yahoo for instance not only has the chart wrong but they pulled a press release from the news archive that should still be present. The FDA approval of the Ahn Thrombectomy Catheter. Now why they did that is as much a mystery as the error in the chart. americanbiomed.com Regards, Jeff